Supplementary Materials

Supplementary Material for:

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody

Chad E. Mire, Joan B. Geisbert, Viktoriya Borisevich, Karla A. Fenton, Krystle N. Agans, Andrew I. Flyak, Daniel J. Deer, Herta Steinkellner, Ognian Bohorov, Natasha Bohorova, Charles Goodman, Andrew Hiatt, Do H. Kim, Michael H. Pauly, Jesus Velasco, Kevin J. Whaley, James E. Crowe Jr., Larry Zeitlin,* Thomas W. Geisbert*

*Corresponding author. Email: twgeisbe{at}utmb.edu (T.W.G.); larry.zeitlin{at}mappbio.com (L.Z.)

Published 5 April 2017, Sci. Transl. Med. 9, eaai8711 (2017)
DOI: 10.1126/scitranslmed.aai8711

This PDF file includes:

  • Fig. S1. Postexposure protection of guinea pigs infected with GPA MARV virus and treated 2 dpi with a single dose of mAb.
  • Fig. S2. MARV antigen in NHPs treated or untreated with MR191-N on 5 and 8 dpi.
  • Fig. S3. Neutralization sensitivity of virus inoculum and virus isolated from MARV Tx-5.
  • Fig. S4. RAVV antigen in NHPs treated or untreated with MR191-N on 5 and 8 dpi.
  • Table S1. Control or MR191-N–treated Marburg or Ravn virus–inoculated NHPs.
  • Table S2. Single-nucleotide polymorphism changes from MARV deep sequencing data.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S3 (Microsoft Excel format). Primary data.

[Download Table S3]